Vascular and metabolic effects of angiotensin II receptor blockers

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 173-189

  Barra, Silvia ^a   Vitagliano, Alice ^a   Cuomo, Vittoria ^b   Vitagliano, Giancarlo ^a   Gaeta, Giovanni ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Angiotensin receptor blocking drugs; Carotid intima media thickness; Endothelial dysfunction; Type 2 diabetes mellitus prevention; Uric acid; Vascular inflammation

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; ENALAPRIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; IMIDAPRIL; IRBESARTAN; LOSARTAN; NATEGLINIDE; NISOLDIPINE; OLMESARTAN; RAMIPRIL; SARALASIN; TELMISARTAN; THIOCTIC ACID; URIC ACID; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICOSURIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFLAMMATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RISK REDUCTION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URIC ACID BLOOD LEVEL; VASCULITIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; METABOLISM; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR DISEASES; CAROTID STENOSIS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; HYPERTENSION; INFLAMMATION;

EID: 65649122686     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802653180     Document Type: Review

References (100)

1. Bright R. Tubular view of the morbid appearances in 100 cases connected with albuminous urine: With observations. Guy's Hosp Rep 1836;1:380-400
2. Volhard F. Nieren und ableitende Harnwege. In: Bergmann G, Staehelin R, editors, Handbuch der Inneren Medizin. Berlin: Springer Verlag; 1931;6. p. 1-1023
3. Tiegerstedt R, Bergman PG. Niere und Kreislauf. Skand Arch Physiol 1898;8:223-271
4. Goldblatt H, Lynch J, Hanzal RF, et al. Studies on experimental hypertension, I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379
5. Braun-Menéndez E, Fasciolo JC, Leloir LF, et al. La sustancia hipertensora de la sangre del riñón isquemiado. Rev Soc Arg Biol 1939;15:420-425
6. Basso N, Terragno NA. History about the discovery of the Renin-Angiotensin System. Hypertension 2001;38:1246-1249 (Pubitemid 34033396)
7. Inagami T. A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 1998;32:953-7 • An excellent review on the history of the discovery of the renin-angiotensin system.
8. Ondetti MA, Williams NJ, Sabo EF, et al. Angiotensin-converting enzyme from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971;10:4033-4039
9. Furakawa Y, Kishimoto S, Nishikawa K. Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patent issued to Takeda Chemical Industries Ltd. on July 20, 1982, and October 19, 1982, respectively. U.S. Patents 4340598 and 4350040, Japan, Osaka, 1982
10. Siegl PK. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens Suppl 1993;11:S19-22 (Pubitemid 23120556)
11. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev 1977;57:313-370 (Pubitemid 8097628)
12. Ferrario CM, Iyer SN. Angiotensin-(1-7): A bioactive fragment of the renin-angiotensin system. Regul Pept 1998;78:13-18
13. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991;17:720-721
14. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992;182:388-394
15. de Gasparo M, Catt KJ, Inagami T, et al .International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472
16. Swanson GN, Hanesworth JM, Sardinia MF, et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992;40:409-419
17. Jarvis MF, Gessner GW, Ly CQ. The angiotensin hexapeptide 3-8 fragment potently inhibits [125I]angiotensin II binding to non-AT1 or -AT2 recognition sites in bovine adrenal cortex. Eur J Pharmacol 1992;219:319-322
18. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999;39:547-559 (Pubitemid 30629034)
19. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251 (Pubitemid 23191415)
20. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29 (Pubitemid 27037846)
21. Ross R. Mechanisms of disease: atherosclerosis, an inflammatory disease. N Engl J Med 1999;340:115-26 •• A classic description of the atherosclerotic lesion and its progression.
22. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-1272
23. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1223-1229 (Pubitemid 29477275)
24. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin converting enzyme inhibition prevents arterial nuclear factor kB activation, MCP-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-1541
25. Prasad A, Koh KK, Schenke WH, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001;142:248-253 (Pubitemid 32706282)
26. Tan K, Chow W, Wong Y, et al. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria. Diabetes Care 2002;25;1254
27. Andersen S, Schalkwijk CG, Stehouwer CD, et al. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 2000;23:1031-1032 (Pubitemid 30480045)
28. Jilma B, Li-Saw-Hee FL, Wagner OF, et al. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond) 2002;103:131-136 (Pubitemid 34886304)
29. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-1212 (Pubitemid 34764875)
30. Koh KK, Quon MJ, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006;108:96-100 (Pubitemid 43324913)
31. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005;111:343-348 (Pubitemid 40165342)
32. Fliser D, Buchholz K, Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-1107
33. Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116-2123 (Pubitemid 38686812)
34. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
35. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 •• The first study demonstrating reduced morbidity/mortality beyond blood pressure lowering with ARB versus beta-blocking drug. (Pubitemid 34286536)
36. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new onset-diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-1886 (Pubitemid 35041980)
37. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886 (Pubitemid 36677151)
38. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-1574 (Pubitemid 36994137)
39. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
40. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781 (Pubitemid 37093918)
41. Granger CB, Mcmurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776 (Pubitemid 37093917)
42. Mcmurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
43. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53 (Pubitemid 40962568)
44. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96 • A meta-analysis of all the relevant published studies evaluating the effects of RAS inhibition on the incidence of type 2 diabetes mellitus.
45. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 • The largest study comparing ARB, ACE-inhibitor and their association in high-risk patients.
46. Yusuf S, Gerstein HC, Hoowerf B, et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-1885 (Pubitemid 33010241)
47. Yusuf S, Teo K, Anderson C, et al. Telmisartan randomised Assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183
48. The Dream, Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62 • The only published clinical trial evaluating the effect of an ACE inhibitor on new-onset T2DM as the primary end point.
49. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004;30:498-505
50. Mcguire DK, Winterfield JR, Rytlewski JA, et al. Blocking the renin-angiotensinaldosterone system to prevent diabetes mellitus. Diabetes Vasc Dis Res 2008;5:59-66
51. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414 (Pubitemid 38339910)
52. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-379 (Pubitemid 38339177)
53. Feig ID, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-1821
54. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21:1157-1162
55. Elliott WJ, Calhoun DA, Delucca PT, et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001;23:1166-1179 (Pubitemid 32804112)
56. Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-1049 (Pubitemid 38251080)
57. Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006;19;208-213 (Pubitemid 43350176)
58. Dang A, Zhang Y, Liu G, et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 2006;20;45-50
59. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115
60. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-118 (Pubitemid 27104258)
61. Yataco AR, Corretti MC, Gardner AW, et al. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 1999;83:754-758 (Pubitemid 29115450)
62. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474 (Pubitemid 24344241)
63. Mangoni AA, Giannattasio C, Brunani A, et al. Radial artery compliance in young, obese, normotensive subjects. Hypertension 1995;26:984-988
64. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000;101:2349-2354 (Pubitemid 30329123)
65. Skeggs LT, Jr, Marsh WH, Kahn JR, Shumway NP. The existence of two forms of hypertensin. J Exp Med 1954;99:275-282
66. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910 (Pubitemid 37059752)
67. Tomás JP, Moya JL, Barrios V, et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006;24:2109-2114 (Pubitemid 44371279)
68. Hornig B, Kohler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor- dependent mechanism. Hypertension 2003;41:1092-1095 (Pubitemid 36548608)
69. Warnholtz A, Ostad MA, Heitzer T, et al. AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Atherosclerosis 2007;194:439-445 (Pubitemid 47513075)
70. von zur Muhlen B, Kahan T, Hagg A, et al. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001;19:1813-1818
71. Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-371
72. Higuchi T, Abletshauser C, Nekolla SG, et al. Effect of the angiotensin receptor blocker valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-812 (Pubitemid 350131388)
73. Hirooka Y, Kimura Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008;30:267-276 (Pubitemid 351556172)
74. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-128 (Pubitemid 36143430)
75. Karalliedde J, Smith A, Deangelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-1623
76. Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-1149 (Pubitemid 47375012)
77. Leu HB, Charng MJ, Ding PY. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. Jpn Heart J 2004;45:623-635 (Pubitemid 41518867)
78. Donald AE, Charakida M, Cole TJ, et al. Invasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006;48:1846-1850
79. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250-256
80. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-1437 (Pubitemid 27375333)
81. O'leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22
82. Held C, Hjemdahl P, Eriksson SV, et al. Prognostic implication of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001;22:62-72 (Pubitemid 32622190)
83. Ariff B, Zambanini A, Vamadeva S, et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006;37:2381-2384 (Pubitemid 44337189)
84. Ono H, Minatoguchi S, Watanabe K, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008;31:271-279
85. Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007;1:97-106
86. Ludwig M, Stapff M, Ribeiro A, et al. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clin Ther 2002;24:1175-1193 (Pubitemid 34833239)
87. Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005;14:177-183 (Pubitemid 41015717)
88. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res 2005;28:111-116 (Pubitemid 41201988)
89. Sonoda M, Aoyagi T, Takenaka K, et al. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J 2008;49:95-103
90. Okura T, Watanabe S, Kurata M, et al. Long-term effects of angiotensin ii receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens 2008;30:415-422 (Pubitemid 352009300)
91. Mörtsell D, Malmqvist K, Held C, et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007;261:472-479 (Pubitemid 46587719)
92. Petrovic I, Petrovic D, Vukovic N, et al. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33 (Suppl 1):39-49A (Pubitemid 41397908)
93. Heart Outcomes, Evaluation Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the Hope study and Micro-Hope substudy. Lancet 2000;355:253-259 (Pubitemid 30068516)
94. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166:2191-2201 (Pubitemid 44748765)
95. Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424-429
96. Cohn JA, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotension-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675 (Pubitemid 33126822)
97. Pfeffer MA, Mcmurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906 (Pubitemid 37409706)
98. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
99. Brown MJ. Aliskiren. Circulation 2008;118:773-784
100. Parving H-H, Persson F, Lewis JB, et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008;358:2433-2436 (Pubitemid 351793017)